Thymmune Therapeutics

About

Thymmune Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company focuses on restoring immune function through its innovative thymic cell engineering platform, which utilizes machine learning and induced pluripotent stem cell (iPSC) technology. Thymmune develops scalable therapies aimed at addressing immune decline associated with aging and various diseases, including immunodeficiencies and autoimmune conditions. The company's lead candidate, THY-001, is a stem-cell-derived thymic cell therapy designed for patients with athymia. Thymmune's platform allows for the mass production of thymic epithelial progenitor (TEP) cells, supporting clinical scalability and reproducibility. The company is actively engaged in preclinical research and has received significant funding, including $1 million from NIH/NIAID for THY-001 development and a total of $600 million in funding to date. Thymmune operates with a small team and is committed to advancing treatments for immune-mediated diseases.